Document is current
Any future updates will be listed below
-
Authors
van de Pol, Natasja
Visser, Elyke H.
van Noord, Desirée
van der Woude, C. Janneke
de Vries, Annemarie C.
de Jonge, Vincent
West, Rachel L.
-
Funding
Funding for this research was provided by:
Transition funds provided by Dutch health insurers
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 28 March 2025
First Online: 17 April 2025
Declarations
:
: DvN has served on advisory boards for Janssen, Takeda, Abbvie, Galapagos, and Lilly; CJW received grants from ZonMW, Falk, and Pfizer, has received consulting fees from Janssen, Galapagos, and Pfizer, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Ferring and AbbVie, and had leadership roles in the European Crohn’s & Colitis organization and United European Gastroenterology council and the Dutch Association for Gastroenterology (NVGE); ACV has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer; RLW has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring, Pfizer, Galapagos, AbbVie, and Janssen; all other authors declare that they have no conflict of interest.
: This study was approved by the Institutional Review Board (IRB) of the Erasmus University Medical Center, MEC-2022-0737.
